Riskpilot← Back to searchSign inGet full accessNORMEDI NORDIC AS
ASActiveOrg 913125304Baglergaten 16, 3111 TønsbergWholesale of pharmaceutical and medical goods · NACE 4646Est. 20143 employeeswww.normedi.com
Revenue 2024
NOK 9,8M
+62% vs 2023
EBITDA margin
-0.4%
-133% vs 2023
Equity ratio
58.8%
Financial strength
Net profit 2024
NOK -44K
-411% vs 2023
| Revenue | NOK 9,8M | +62% |
| EBITDA | NOK -36K | -133% |
| Net profit | NOK -44K | -411% |
| Total assets | NOK 3,8M | +18% |
| Equity | NOK 2,3M | -2% |
| Employees | 3 | — |
Legal name
NORMEDI NORDIC AS
Org number
913125304
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
25. januar 2014
Share capital
NOK 500 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Salg og markedsføring av medisintekniske produkter i norden samt investeringer i andre selskaper.
Address
Baglergaten 16, 3111 Tønsberg
Website
www.normedi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 678 | 6 192 | 6 773 | 6 073 | 9 835 |
| Staff expenses | −3 071 | −3 602 | −3 626 | −2 793 | −6 961 |
| EBITDA | −113 | 346 | 362 | 111 | −36 |
| Depreciation & amort. | −29 | −71 | −74 | −98 | −19 |
| EBIT | −142 | 274 | 288 | 12 | −56 |
| Net financials | 6 965 | 6 554 | −293 | −12 | 11 |
| Profit before tax | 6 823 | 6 828 | −4 | 0 | −44 |
| Tax | 9 | 12 | 6 | 9 | −0 |
| Net profit | 6 814 | 6 816 | −10 | −9 | −44 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 9 515 | 9 651 | 3 546 | 3 258 | 3 836 |
| Equity | 1 571 | 2 185 | 2 309 | 2 300 | 2 256 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 7 944 | 7 466 | 1 238 | 958 | 1 580 |
| Total debt | 7 944 | 7 466 | 1 238 | 958 | 1 580 |
EBITDA margin
-0.4%
This company
15.8%
Market median
-103% vs market
20202024
Equity ratio
58.8%
This company
38.2%
Market median
+54% vs market
20202024
Return on equity
-2.0%
This company
18.4%
Market median
-111% vs market
20202024
Net profit margin
-0.5%
This company
8.1%
Market median
-106% vs market
20202024
Asset turnover
2.56×
This company
1.12×
Market median
+129% vs market
20202024
Debt / equity
0.70×
This company
0.62×
Market median
+13% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-09-30
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (1) | ||
| Chairman | 2014 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Hologic Ggo 4 Ltd | Company | 97.93% | 97.93% | 2024 |
| Individual | 73% | 73% | 2022 | |
| Individual | 11.83% | 11.83% | 2022 | |
| Individual | 6.83% | 6.83% | 2022 | |
| Company | 2.07% | 2.07% | 2024 | |
| Individual | 1.8% | 1.8% | 2022 | |
| Individual | 1.53% | 1.53% | 2022 | |
| Individual | 1.5% | 1.5% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NORMEDI NORDIC AS 
NORMEDI NORGE ASBoard members of NORMEDI NORDIC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øystein Granne Norling | Chairman | 0 companies |
| Jesper Steffensen | Board of Directors | 0 companies |
| Joao Paulo Falcao Malagueira | Board of Directors | 0 companies |
| Michelangelo Stefani | Chairman | 0 companies |